Comparative analysis of MVA-CD40L and MVA-TRICOM vectors for enhancing the immunogenicity of chronic lymphocytic leukemia (CLL) cells.
Adenoviral transduction with CD40L and poxviral transduction with B7-1, ICAM-1, and LFA-3 (TRICOM) have been used to enhance the antigen-presenting capacity of chronic lymphocytic leukemia (CLL) cells. This study compares the same vector (modified vaccinia virus strain Ankara (MVA)) encoding CD40L or TRICOM for its ability to enhance the immunogenicity of CLL cells. CLL cells from some patients showed differential responses to each vector in terms of induction of autologous T-cell responses. This study supports the rationale for the use of CLL cells modified ex vivo with pre-specified recombinant MVA vectors as a whole tumor-cell vaccine for immunotherapy in CLL patients.
Litzinger
Mary T
MT
Laboratory of Tumor Immunology and Biology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA.
Foon
Kenneth A
KA
Tsang
Kwong-Yok
KY
Schlom
Jeffrey
J
Palena
Claudia
C
D018122:B7-1 Antigen / Q000235:genetics*; D023201:CD40 Ligand / Q000235:genetics*; D018968:CD58 Antigens / Q000235:genetics*; D019496:Cancer Vaccines / Q000276:immunology*; D005822:Genetic Vectors; D006801:Humans; D007167:Immunotherapy; D018799:Intercellular Adhesion Molecule-1 / Q000235:genetics*; D015451:Leukemia, Lymphocytic, Chronic, B-Cell / Q000276:immunology / Q000628:therapy*; D008213:Lymphocyte Activation; D013601:T-Lymphocytes / Q000276:immunology; D014616:Vaccinia virus / Q000235:genetics*
D018122:B7-1 Antigen; D018968:CD58 Antigens; D019496:Cancer Vaccines; D018799:Intercellular Adhesion Molecule-1; D023201:CD40 Ligand